First rapid guidelines on Covid 19 by NICE

Written By :  Dr. Kamal Kant Kohli
Published On 2020-03-23 06:30 GMT   |   Update On 2020-03-23 10:20 GMT

National Institute for Health and Care Excellence (NICE) has published its first rapid guidelines on the care of people with suspected and confirmed COVID-19, and in patients without COVID-19.After SARS and MERS, COVID-19 has been the third pandemic caused by a coronavirus that has led to worldwide panic.The new guidelines essentially cover management of patients in critical care,...

Login or Register to read the full article

National Institute for Health and Care Excellence (NICE) has published its first rapid guidelines on the care of people with suspected and confirmed COVID-19, and in patients without COVID-19.

After SARS and MERS, COVID-19 has been the third pandemic caused by a coronavirus that has led to worldwide panic.

The new guidelines essentially cover management of patients in critical care, the management of patients who are having kidney dialysis and the management of patients who are receiving systemic anticancer treatments.

COVID-19 rapid guideline for critical care patients

1.All patients on admission to hospital, irrespective of COVID-19 status, should continue to be assessed for frailty using a recognised frailty score (for example, the Clinical Frailty Scale [CFS]).

2.The risks and benefits and likely outcomes should be discussed with patients, carers or advocates and families using decision support tools (where available) so that they can make informed decisions about their treatment wherever possible.

3.In cases of confirmed COVID-19 patients, decisions about admission to critical care should be made on the basis of medical benefit, taking into account the likelihood that the person will recover to an outcome that is acceptable to them and within a period of time consistent with the diagnosis.

COVID-19 rapid guideline: delivery of systemic anticancer treatments

1.Where decisions need to be made about prioritising patients for treatment, these need to take into account the level of immunosuppression associated with individual treatments and cancer types, and any other patient-specific risk factors. They should also balance the risk from cancer not being treated optimally versus the risk of becoming seriously ill if they contract COVID-19 because of immunosuppression.

2.In patients where changes need to be made to usual care because of system pressures, the guideline says consideration should be given to delivering treatment in different and less immunosuppressive regimens, different locations or via another route of administration.

COVID-19 rapid guideline in CKD: dialysis service delivery

1.All patients with suspected COVID-19 should be assessed to see whether dialysis could be delayed until their COVID-19 status is known.

2.It has also been recommended that outpatient transport services should get patients to their dialysis as scheduled to avoid their condition deteriorating. It should also be ensured that appropriate transport services are available by finding out what current transport providers are prepared to provide, and whether there are alternative providers if the current providers will not transport patients infected with COVID-19.

NICE has said that further guidelines will be announced in due course but are likely to include: symptom management; patients receiving radiotherapy; and patients with rheumatoid arthritis. NICE will publish new guidelines each week until the full set has been completed, based on the priorities for patients and the NHS.

The guidelines are being produced in collaboration with NHS England/Improvement and a cross-specialty clinical group, supported by the specialist societies and Royal Colleges. 

Tags:    
Article Source : National Institute for Health and Care Excellence

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News